This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Earle, C. C. Articles by Neumann, P. J. Search for Related Content PubMed PubMed Citation Articles by Earle, C. C. Articles by Neumann, P. J. Social Bookmarking                            What's this?

Systematic Overview of Cost-Utility Assessments in Oncology

From the Center for Outcomes and Policy Research, Department of Adult Oncology, Dana-Farber Cancer Institute; and Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA.

Address reprint requests to Craig Earle, MD, MSc, FRCPC, Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, 44 Binney St, 454-STE 21-24, Boston, MA 02115; email craig_earle{at}dfci.harvard.edu

PURPOSE: Cost-utility analyses (CUAs) present the value of an intervention as the ratio of its incremental cost divided by its incremental survival benefit, with survival weighted by utilities to produce quality-adjusted life years (QALYs). We critically reviewed the CUA literature and its role in informing clinical oncology practice, research priorities, and policy.

METHODS: The English-language literature was searched between 1975 and1997 for CUAs. Two readers abstracted from each article descriptions of the clinical situation and patients, the methods used, study perspective, the measures of effectiveness, costs included, discounting, and whether sensitivity analyses were performed. The readers then made subjective quality assessments. We also extracted utility values from the reviewed papers, along with information on how and from whom utilities were measured.

RESULTS: Our search yielded 40 studies, which described 263 health states and presented 89 cost-utility ratios. Both the number and quality of studies increased over time. However, many studies are at variance with current standards. Only 20% of studies took a societal perspective, more than a third failed to discount both the costs and QALYs, and utilities were often simply estimates from the investigators or other physicians.

CONCLUSION: The cost-utility literature in oncology is not large but is rapidly expanding. There remains much room for improvement in the methodological rigor with which utilities are measured. Considering quality-of-life effects by incorporating utilities into economic studies is particularly important in oncology, where many therapies obtain modest improvements in response or survival at the expense of nontrivial toxicity.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. H. Ahern and Y. Shen Cost-Effectiveness Analysis of Mammography and Clinical Breast Examination Strategies: A Comparison with Current Guidelines Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 718 - 725. [Abstract] [Full Text] [PDF]

				D. Regge, C. Hassan, P. J. Pickhardt, A. Laghi, A. Zullo, D. H. Kim, F. Iafrate, and S. Morini Impact of Computer-aided Detection on the Cost-effectiveness of CT Colonography Radiology, February 1, 2009; 250(2): 488 - 497. [Abstract] [Full Text] [PDF]

				A. DAVIES, M. A. CIFALDI, O. G. SEGURADO, and M. H. WEISMAN Cost-Effectiveness of Sequential Therapy with Tumor Necrosis Factor Antagonists in Early Rheumatoid Arthritis J Rheumatol, January 1, 2009; 36(1): 16 - 26. [Abstract] [Full Text] [PDF]

				H. J. Otero, F. J. Rybicki, D. Greenberg, and P. J. Neumann Twenty Years of Cost-effectiveness Analysis in Medical Imaging: Are We Improving? Radiology, December 1, 2008; 249(3): 917 - 925. [Abstract] [Full Text] [PDF]

				P. V. Pandharipande, M. G. Harisinghani, E. M. Ozanne, M. C. Specht, C. Hur, J. M. Lee, and G. S. Gazelle Staging MR Lymphangiography of the Axilla for Early Breast Cancer: Cost-Effectiveness Analysis Am. J. Roentgenol., November 1, 2008; 191(5): 1308 - 1319. [Abstract] [Full Text] [PDF]

				Y.-C. T. Shih and M. T. Halpern Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean? CA Cancer J Clin, July 1, 2008; 58(4): 231 - 244. [Abstract] [Full Text] [PDF]

				R. A. Miksad, L. Schnipper, and M. Goldstein Does a Statistically Significant Survival Benefit of Erlotinib Plus Gemcitabine for Advanced Pancreatic Cancer Translate Into Clinical Significance and Value? J. Clin. Oncol., October 1, 2007; 25(28): 4506 - 4507. [Full Text] [PDF]

				G. H. Lyman Editorial: Gene Expression Profile Assays As an Aid in Treatment Decision Making in Early-Stage Breast Cancer J. Oncol. Pract, July 1, 2007; 3(4): 187 - 188. [Full Text] [PDF]

				J. N. Cormier, Y. Xing, M. Ding, S. B. Cantor, K. J. Salter, J. E. Lee, P. F. Mansfield, J. E. Gershenwald, and M. I. Ross Cost Effectiveness of Adjuvant Interferon in Node-Positive Melanoma J. Clin. Oncol., June 10, 2007; 25(17): 2442 - 2448. [Abstract] [Full Text] [PDF]

				P. A. Grusenmeyer and Y.-N. Wong Interpreting the Economic Literature in Oncology J. Clin. Oncol., January 10, 2007; 25(2): 196 - 202. [Abstract] [Full Text] [PDF]

				W. B. van den Hout, G. W. P. M. Kramer, E. M. Noordijk, and J.-W. H. Leer Cost-Utility Analysis of Short- Versus Long-Course Palliative Radiotherapy in Patients With Non-Small-Cell Lung Cancer J Natl Cancer Inst, December 20, 2006; 98(24): 1786 - 1794. [Abstract] [Full Text] [PDF]

				E. A. Perez Appraising Adjuvant Aromatase Inhibitor Therapy Oncologist, November 1, 2006; 11(10): 1058 - 1069. [Abstract] [Full Text] [PDF]

				R. S. Svatek, J. J. Lee, C. G. Roehrborn, S. M. Lippman, and Y. Lotan The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol. Biomarkers Prev., August 1, 2006; 15(8): 1485 - 1489. [Abstract] [Full Text] [PDF]

				N. K. Stout, M. A. Rosenberg, A. Trentham-Dietz, M. A. Smith, S. M. Robinson, and D. G. Fryback Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst, June 7, 2006; 98(11): 774 - 782. [Abstract] [Full Text] [PDF]

				P. Das, A. K. Ng, C. C. Earle, P. M. Mauch, and K. M. Kuntz Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis Ann. Onc., May 1, 2006; 17(5): 785 - 793. [Abstract] [Full Text] [PDF]

				E. Nadler, B. Eckert, and P. J. Neumann Do oncologists believe new cancer drugs offer good value? Oncologist, February 1, 2006; 11(2): 90 - 95. [Abstract] [Full Text] [PDF]

				J. A. Hayman, M. U. Kabeto, M. J. Schipper, J. E. Bennett, F. A. Vicini, and L. J. Pierce Assessing the Benefit of Radiation Therapy After Breast-Conserving Surgery for Ductal Carcinoma-In-Situ J. Clin. Oncol., August 1, 2005; 23(22): 5171 - 5177. [Abstract] [Full Text] [PDF]

				T. J. Smith, P. J. Coyne, P. S. Staats, T. Deer, L. J. Stearns, R. L. Rauck, R. L. Boortz-Marx, E. Buchser, E. Catala, D. A. Bryce, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM) Ann. Onc., May 1, 2005; 16(5): 825 - 833. [Abstract] [Full Text] [PDF]

				F. E. Johnson, K. S. Virgo, and R. Fossati Follow-Up for Patients With Colorectal Cancer After Curative-Intent Primary Treatment J. Clin. Oncol., April 15, 2004; 22(8): 1363 - 1365. [Full Text] [PDF]

				E. B. Elkin, M. C. Weinstein, E. P. Winer, K. M. Kuntz, S. J. Schnitt, and J. C. Weeks HER-2 Testing and Trastuzumab Therapy for Metastatic Breast Cancer: A Cost-Effectiveness Analysis J. Clin. Oncol., March 1, 2004; 22(5): 854 - 863. [Abstract] [Full Text] [PDF]

				M. van den Brink, W. B. van den Hout, A. M. Stiggelbout, E. Klein Kranenbarg, C. A.M. Marijnen, C. J.H. van de Velde, and J. Kievit Cost-Utility Analysis of Preoperative Radiotherapy in Patients With Rectal Cancer Undergoing Total Mesorectal Excision: A Study of the Dutch Colorectal Cancer Group J. Clin. Oncol., January 15, 2004; 22(2): 244 - 253. [Abstract] [Full Text] [PDF]

				J. Karnon, S. R. D. Johnston, T. Jones, and A. Glendenning A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer Ann. Onc., November 1, 2003; 14(11): 1629 - 1633. [Abstract] [Full Text] [PDF]

				L. N. Venditti, C. P. Venditti, G. T. Berry, P. B. Kaplan, E. M. Kaye, H. Glick, and C. A. Stanley Newborn Screening by Tandem Mass Spectrometry for Medium-Chain Acyl-CoA Dehydrogenase Deficiency: A Cost-Effectiveness Analysis Pediatrics, November 1, 2003; 112(5): 1005 - 1015. [Abstract] [Full Text] [PDF]

				S. Verma and A. L. Ilersich Population-Based Pharmacoeconomic Model for Adopting Capecitabine/Docetaxel Combination Treatment for Anthracycline-Pretreated Metastatic Breast Cancer Oncologist, June 1, 2003; 8(3): 232 - 240. [Abstract] [Full Text] [PDF]

				D. T. Gray and D. L. Veenstra Comparative economic analyses of minimally invasive direct coronary artery bypass surgery J. Thorac. Cardiovasc. Surg., March 1, 2003; 125(3): 618 - 624. [Abstract] [Full Text] [PDF]

				W. B. van den Hout, Y. M. van der Linden, E. Steenland, R. G. J. Wiggenraad, J. Kievit, H. de Haes, and J. W. H. Leer Single- Versus Multiple-Fraction Radiotherapy in Patients With Painful Bone Metastases: Cost-Utility Analysis Based on a Randomized Trial J Natl Cancer Inst, February 5, 2003; 95(3): 222 - 229. [Abstract] [Full Text] [PDF]

				P. J. Mahadevia, L. A. Fleisher, K. D. Frick, J. Eng, S. N. Goodman, and N. R. Powe Lung Cancer Screening With Helical Computed Tomography in Older Adult Smokers: A Decision and Cost-effectiveness Analysis JAMA, January 15, 2003; 289(3): 313 - 322. [Abstract] [Full Text] [PDF]

				V. R. Grann and A. I. Neugut Lung Cancer Screening at Any Price? JAMA, January 15, 2003; 289(3): 357 - 358. [Full Text] [PDF]

				G. J. Petruzzelli, J. M. Brockenbrough, D. Vandevender, and S. D. Creech The Influence of Reconstructive Modality on Cost of Care in Head and Neck Oncologic Surgery Arch Otolaryngol Head Neck Surg, December 1, 2002; 128(12): 1377 - 1380. [Abstract] [Full Text] [PDF]

				T. Jefferson, V. Demicheli, and L. Vale Quality of Systematic Reviews of Economic Evaluations in Health Care JAMA, June 5, 2002; 287(21): 2809 - 2812. [Abstract] [Full Text] [PDF]

				J. H. Lee, H. A. Glick, J. A. Hayman, and L. J. Solin Decision-Analytic Model and Cost-Effectiveness Evaluation of Postmastectomy Radiation Therapy in High-Risk Premenopausal Breast Cancer Patients J. Clin. Oncol., June 1, 2002; 20(11): 2713 - 2725. [Abstract] [Full Text] [PDF]

				D. Hershman, V. Sundararajan, J. S. Jacobson, D. F. Heitjan, A. I. Neugut, and V. R. Grann Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis J. Clin. Oncol., January 1, 2002; 20(1): 9 - 16. [Abstract] [Full Text] [PDF]